Precision Biopsy, LLC was formed in partnership with Allied Minds to develop and commercialize novel technology for the accurate diagnosis of prostate cancer. The company’s diagnostic technology uses advanced spectroscopy imaging techniques in combination with tissue biopsy. This unique ability seeks to eliminate random prostate biopsies that are subject to sampling errors and can lead to inaccurate grading and staging of the disease.

The scientific founders, professors Priya Werahara and John Daily of the University of Colorado, have long studied the morphology of cancer tissue. Combining their knowledge of advanced spectroscopy techniques has resulted in the ability to image the precise location of cancer in the prostate.



See All

Precision Biopsy Moves into New Facility to Ramp Progress

Precision Biopsy Moves into New Facility to Ramp Progress While Cultivating Unique Collaboration between Academia and Industry AURORA, Colo. - July 31, 2015 &n..


Precision Biopsy Appoints Amir Tehrani as CEO, Successful Completion of Phase I Clinical Trials

Denver, Colorado -- Precision Biopsy is pleased to announce that Amir Tehrani has joined as Chief Executive Officer to manage commercial expansion after the company succes..

Please visit Precision Biopsy at

Contact Precision Biopsy

  • • Required
  • Captcha Image
  • Phone Email

Privacy Policy Terms of Use